Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, developed by Arecor using the Company’s patented technology, Arestat™. This is the first license under a multi-product development agreement between Inhibrx and Arecor.
INBRX-101 is a precisely engineered recombinant human Alpha-1 Antitrypsin Fc-fusion protein for the treatment of Alpha-1 antitrypsin deficiency (AATD). AATD is an underdiagnosed inherited orphan genetic disease that can cause serious lung disease in adults and/or liver disease at any age. Arestat™ is a world leading, innovative and proprietary formulation technology platform which significantly enhances the properties of therapeutic proteins and peptides. This collaboration demonstrates the unique capability of the Arestat™ technology to deliver superior reformulations of complex fusion proteins in this case for treatment of an orphan disease.